[CLBS] Caladrius Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Hospital/Nursing Management

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 2.93 Change: -0.21 (-6.69%)
Ext. hours: Change: 0 (0%)

chart CLBS

Refresh chart

Strongest Trends Summary For CLBS

CLBS is in the medium-term down -42% below S&P in 5 months and down -55% in 1 year. In the long-term down -100% below S&P in 27 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities7.49 M Cash From Investing Activities6.7 M Cash From Operating Activities-14.24 M Gross Profit-200 K
Net Profit-19.19 M Operating Profit-18.09 M Total Assets118.81 M Total Current Assets29.02 M
Total Current Liabilities17.46 M Total Debt16.72 M Total Liabilities68.41 M Total Revenue3.17 M
Technical Data
High 52 week8.64 Low 52 week2.83 Last close3 Last change-3.23%
RSI46.22 Average true range0.21 Beta0.51 Volume68.63 K
Simple moving average 20 days0.47% Simple moving average 50 days-9.35% Simple moving average 200 days-32.7%
Performance Data
Performance Week5.63% Performance Month-0.66% Performance Quart-27.88% Performance Half-38.52%
Performance Year-26.47% Performance Year-to-date-15.73% Volatility daily2.82% Volatility weekly6.31%
Volatility monthly12.94% Volatility yearly44.82% Relative Volume332.17% Average Volume31.05 K
New High New Low-4.56%

News

2019-06-04 08:30:00 | Caladrius Biosciences Completes Enrollment in Phase 2 ESCaPE-CMD Trial for Coronary Microvascular Dysfunction

2019-05-10 18:11:18 | Edited Transcript of CLBS earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-09 16:05:00 | Caladrius Biosciences Reports 2019 First Quarter Financial Results and Provides Corporate Update

2019-05-07 08:30:00 | Caladrius Biosciences to Participate at the Upcoming May Conferences

2019-05-02 08:30:00 | Caladrius Biosciences to Host 2019 First Quarter Financial Results Conference Call on Thursday, May 9, 2019 at 4:30 p.m. Eastern Time

2019-04-25 14:23:27 | How Does Caladrius Biosciences, Inc. NASDAQ:CLBS Affect Your Portfolio Volatility?

2019-04-03 08:30:00 | Caladrius Biosciences to Participate in Upcoming Conferences

2019-03-14 16:23:00 | Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results

2019-03-14 16:20:00 | Caladrius Biosciences announces Purchase Agreement with Lincoln Park Capital for up to $26 million

2019-03-13 16:05:00 | Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time

2019-03-11 14:20:37 | What Kind Of Shareholder Appears On The Caladrius Biosciences, Inc.’s NASDAQ:CLBS Shareholder Register?

2019-03-11 08:30:00 | Caladrius Biosciences to Present at the Alliance for Regenerative Medicine 7th Annual Cell & Gene Therapy Investor Day

2019-02-13 17:26:21 | Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

2019-02-05 08:00:00 | Caladrius Biosciences to Present at Upcoming February Conferences

2019-01-23 09:04:02 | What Makes Caladrius Biosciences CLBS a New Buy Stock

2019-01-07 08:00:00 | Caladrius Biosciences to Participate in Upcoming January Conferences

2018-11-15 07:25:00 | Recent Analysis Shows Escalade, Caladrius Biosciences, LightInTheBox Holding Co., Vishay Intertechnology, Ceridian HCM Holding, and Avista Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-09 08:30:00 | Caladrius Biosciences to Participate in the Inv€$tival Showcase in Partnership with Jefferies and the Jefferies 2018 London Healthcare Conference

2018-11-08 16:05:00 | Caladrius Biosciences Reports 2018 Third Quarter Financial Results

2018-11-08 08:30:00 | Caladrius Biosciences Appoints Cynthia Schwalm to Board of Directors

2018-11-02 08:00:00 | Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET

2018-10-01 08:36:54 | Caladrius Biosciences Inc NASDAQ:CLBS: How Does It Impact Your Portfolio?

2018-09-27 08:00:00 | Caladrius Biosciences to Participate in Upcoming October Conferences

2018-09-21 11:24:03 | Caladrius Biosciences CLBS Shares March Higher, Can It Continue?

2018-09-12 09:30:01 | Is Caladrius Biosciences CLBS Stock Outpacing Its Medical Peers This Year?

2018-09-11 08:00:00 | Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region

2018-08-09 16:05:00 | Caladrius Biosciences Reports 2018 Second Quarter and First Six Months Financial Results

2018-08-09 14:30:00 | Caladrius Biosciences, Inc. to Host Earnings Call

2018-08-02 08:00:00 | Caladrius Biosciences to Host Second Quarter 2018 Financial Results Conference Call on Thursday, August 9, 2018 at 4:30 p.m. ET

2018-06-20 08:00:00 | Today's Research Reports on Stocks to Watch: Sarepta Therapeutics and Caladrius Biosciences

2018-06-19 08:00:00 | Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

2018-06-05 08:00:00 | Caladrius Biosciences Sells Rights to Counter-Flow Centrifugation System to Hitachi Chemical Advanced Therapeutics Solutions

2018-05-10 16:05:00 | Caladrius Biosciences Reports 2018 First Quarter Financial Results

2018-05-10 09:39:50 | For Diabetes Patients, Management Solutions Are As Critical As Medications

2018-05-07 08:00:00 | Caladrius Biosciences to Participate at the 15th International Symposium on Cardiovascular Regeneration and Repair

2018-05-03 08:00:00 | Caladrius Biosciences to Host First Quarter 2018 Financial Results Conference Call on Thursday, May 10, 2018 at 4:30 p.m. Eastern Time

2018-04-20 07:20:00 | Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure

2018-04-10 08:00:00 | Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia

2018-04-09 16:00:00 | Caladrius Biosciences to Participate at Upcoming April Conferences

2018-04-03 08:00:00 | Caladrius Biosciences to Present at The MicroCap Conference

2018-03-22 16:05:00 | Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results

2018-03-22 12:00:00 | Caladrius Biosciences, Inc. to Host Earnings Call

2018-03-15 08:00:00 | Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time

2018-03-13 08:00:00 | Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan

2018-03-08 16:05:00 | Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

2018-03-08 08:00:00 | Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes

2018-03-06 08:00:00 | Caladrius Biosciences Acquires an Exclusive License to a Late Stage CD34+ Cell Therapy Program for the Treatment of Refractory Angina

2018-02-07 08:00:00 | Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference

2018-01-18 08:00:00 | Caladrius Biosciences Announces Completion of Enrollment of Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes

2017-12-08 12:33:53 | ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017